A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

NCT06063317 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Portfolio prioritization

Conditions

Solid Tumor, Adult

Interventions

BIOLOGICAL: CF33-CD19 IT Monotherapy
BIOLOGICAL: CF33-CD19 IV Monotherapy
BIOLOGICAL: CF33-CD19 IT Combination
BIOLOGICAL: CF33-CD19 IV Combination
DRUG: Blinatumomab
DRUG: Hydroxyurea

Sponsor

Imugene Limited